Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy
暂无分享,去创建一个
C. Elger | M. J. García | A. Domínguez-Gil | M. Otero | D. S. Buelga | J. Santos-Borbujo | N. Rivas | M. García | A. Domínguez‐gil
[1] G. Shakya,et al. Therapeutic drug monitoring of antiepileptic drugs. , 2008, JNMA; journal of the Nepal Medical Association.
[2] T. Tomson,et al. Therapeutic monitoring of antiepileptic drugs for epilepsy. , 2007, The Cochrane database of systematic reviews.
[3] V. Biton. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy , 2006, Expert opinion on drug metabolism & toxicology.
[4] I. Baldeiras,et al. Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring , 2006, European Journal of Clinical Pharmacology.
[5] J. Sackellares,et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures , 2005, Neurology.
[6] M. Bialer. The Pharmacokinetics and Interactions of New Antiepileptic Drugs: An Overview , 2005, Therapeutic drug monitoring.
[7] L. Hirsch,et al. Effect of antiepileptic drug comedication on lamotrigine clearance. , 2005, Archives of neurology.
[8] E. Perucca,et al. An Introduction to Antiepileptic Drugs , 2005, Epilepsia.
[9] Wolfgang Löscher,et al. The neurobiology of antiepileptic drugs , 2004, Nature Reviews Neuroscience.
[10] M. Zhong,et al. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data , 2004, Journal of clinical pharmacy and therapeutics.
[11] R. Jelliffe,et al. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage , 2004, Journal of clinical pharmacy and therapeutics.
[12] T. Tomson,et al. Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs , 2003, Therapeutic drug monitoring.
[13] M. Baraldo,et al. Therapeutic Drug Monitoring of Lamotrigine in Patients Suffering from Resistant Partial Seizures , 2002, European Neurology.
[14] T. May,et al. Does Lamotrigine Influence Valproate Concentrations? , 2002, Therapeutic drug monitoring.
[15] L. Dupuis,et al. Therapeutic Drug Monitoring of Lamotrigine , 2002, The Annals of Pharmacotherapy.
[16] F. Keller,et al. Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. , 2002, Epileptic disorders : international epilepsy journal with videotape.
[17] S. Tett,et al. Population Pharmacokinetics of Lamotrigine , 2001, Therapeutic drug monitoring.
[18] G. Anderson,et al. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy , 2000, Epilepsy Research.
[19] A. Kanner,et al. Adding valproate to lamotrigine: A study of their pharmacokinetic interaction , 2000, Neurology.
[20] C Chen,et al. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. , 2000, British journal of clinical pharmacology.
[21] E. Perucca,et al. Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants? , 2000, Clinical pharmacokinetics.
[22] M. García-Sánchez,et al. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data , 1999, Biopharmaceutics & drug disposition.
[23] J. Herranz,et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. , 1999, Therapeutic drug monitoring.
[24] E. Cox,et al. Population Pharmacokinetics of Lamotrigine Adjunctive Therapy in Adults with Epilepsy , 1999, Journal of clinical pharmacology.
[25] A. Domínguez-Gil,et al. Valproate population pharmacokinetics in children , 1999, Journal of clinical pharmacy and therapeutics.
[26] R. Morris,et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. , 1998, British journal of clinical pharmacology.
[27] S. Higuchi,et al. Population‐Based Investigation of Valproic Acid Relative Clearance Using Nonlinear Mixed Effects Modeling: Influence of Drug‐Drug Interaction and Patient Characteristics , 1997, Journal of clinical pharmacology.
[28] W. Garnett,et al. Lamotrigine: pharmacokinetics. , 1997, Journal of child neurology.
[29] L. Ståhle,et al. Lamotrigine drug interactions in a TDM material. , 1997, Therapeutic drug monitoring.
[30] J. Posner,et al. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. , 1997, British journal of clinical pharmacology.
[31] A. Falcão,et al. Carbamazepine population pharmacokinetics in children: mixed-effect models. , 1997, Therapeutic drug monitoring.
[32] Gidal Be,et al. The concentration-effect relationship with lamotrigine (LTG) , 1997 .
[33] U. Specht,et al. Pharmacokinetic Interactions of the New Antiepileptic Drugs , 1996, Clinical pharmacokinetics.
[34] G. Anderson,et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects , 1996, Clinical pharmacology and therapeutics.
[35] M. Brodie,et al. Concentration‐Effect and Concentration‐Toxicity Relations with Lamotrigine: A Prospective Study , 1996, Epilepsia.
[36] P. Glue,et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. , 1996, Therapeutic drug monitoring.
[37] B. Rambeck,et al. Lamotrigine Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.
[38] K. Goa,et al. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. , 1993, Drugs.
[39] Lewis B. Sheiner,et al. Pharmacostatistical modeling for observational data , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[40] Donald R. Stanski,et al. Evaluation of population (NONMEM) pharmacokinetic parameter estimates , 1990, Journal of Pharmacokinetics and Biopharmaceutics.
[41] A. Cohen,et al. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans , 1987, Clinical pharmacology and therapeutics.
[42] T. Tomson,et al. Pharmacokinetic Variability of Newer Antiepileptic Drugs , 2006, Clinical pharmacokinetics.
[43] E. Perucca. Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age , 2006, Clinical pharmacokinetics.
[44] R. Miller,et al. Determination of phenobarbitone population clearance values for South African children , 2004, European Journal of Clinical Pharmacology.
[45] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[46] E. Lynette Mullens. Clinical Experience with Lamotrigine Monotherapy in Adults with Newly Diagnosed Epilepsy , 1998 .
[47] T. Welty,et al. The concentration-effect relationship with lamotrigine (LTG) , 1997, Epilepsia.